Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexinidazole pharmacokinetics in hepatic impairment
NCT05607173Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of Fexinidazole (3 arms), sponsored by Sanofi. Primary endpoints: Maximum plasma concentration for fexinidazole and metabolites M1, M2 and Area under the plasma concentration-time curve for fexinidazole and metabolites M1, M2. Started Jan 2023; status: completed.
02
Drugs
Fexinidazole
Beyond the preview
Go deeper on NCT05607173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607173.